Results 11 to 20 of about 36,441 (245)
In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance [PDF]
Frontiers in MedicineBackgroundActivated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in clinical practice, potentially leading to suboptimal ...
Lin Sun +7 more
doaj +2 more sources
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]
Scientific ReportsDirect oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano +8 more
doaj +2 more sources
Efficacy and Toxicity of Factor Xa Inhibitors
Journal of Pharmacy & Pharmaceutical Sciences, 2013 Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko +4 more
doaj +5 more sources
AN IN-SILICO STUDY OF SOME NATURAL AND SYNTHETIC COMPOUNDS AS POTENTIAL INHIBITORS FOR FACTOR XA [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2022 Recent research has demonstrated the significance of factor Xa and its inhibitors as a possible treatment approach. Since currently approved drugs have a wide variety of side effects, new anticoagulants must be developed.
Lara AlBeik +2 more
doaj +1 more source
Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke [PDF]
Precision and Future Medicine, 2020 In case of any embolic event, treatment strategy should be established according to the pathomechanisms of failure of non-vitamin K oral anticoagulants (NOAC). A 72-year-old man was referred to our hospital with a sudden speech disturbance.
Hyung Jun Kim +3 more
doaj +1 more source
Direct oral anticoagulant: Review article
Journal of Family Medicine and Primary Care, 2022 Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year.
Abdulrahman Nasiri +5 more
doaj +1 more source
F1000Research, 2021 Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana +4 more
doaj +1 more source
TH Open, 2020 SARS-CoV-2 infection (COVID-19) results in local and systemic activation of inflammation and coagulation. In this review article, we will discuss the potential role of coagulation factor Xa (FXa) in the pathophysiology of COVID-19. FXa, a serine protease,
Galit H. Frydman +3 more
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundAnti-factor Xa activity has been suggested as a surrogate parameter for judging the effectiveness of pharmacological thromboprophylaxis with low molecular weight heparins in critically ill patients.
Christoph Dibiasi +6 more
doaj +1 more source
Swiss Medical Weekly, 2023 Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer +5 more
doaj +1 more source